Novel antibodies targeting immune regulatory checkpoints for cancer therapy
Novel antibodies targeting immune regulatory checkpoints for cancer therapy
Cancers must evade or suppress the immune system in order to develop. Better understanding of the molecular regulation governing tumour detection and effective activation of the immune system (so-called immune regulatory checkpoints) has provided new targets for cancer immunotherapy. Therapeutic monoclonal antibodies against these targets are currently undergoing clinical evaluation with more in pre-clinical development; buoyed by the recent licence approval of the anti-CTLA-4 antibody, ipilumumab, for use in melanoma. This article will review the current status of the various antibodies and target molecules being investigated.
immunomodulatory antibodies, monoclonal antibodies, cancer, immunotherapy
Lee, Chern Siang
a3f55150-0839-4f1f-989b-812ed39eea41
Cragg, Mark
ec97f80e-f3c8-49b7-a960-20dff648b78c
Glennie, Martin
9f6f0eff-4560-48c2-80cd-0ec116110ded
Johnson, Peter
3f6068ce-171e-4c2c-aca9-dc9b6a37413f
23 May 2013
Lee, Chern Siang
a3f55150-0839-4f1f-989b-812ed39eea41
Cragg, Mark
ec97f80e-f3c8-49b7-a960-20dff648b78c
Glennie, Martin
9f6f0eff-4560-48c2-80cd-0ec116110ded
Johnson, Peter
3f6068ce-171e-4c2c-aca9-dc9b6a37413f
Lee, Chern Siang, Cragg, Mark, Glennie, Martin and Johnson, Peter
(2013)
Novel antibodies targeting immune regulatory checkpoints for cancer therapy.
British Journal of Clinical Pharmacology.
(doi:10.1111/bcp.12164).
(PMID:23701301)
Abstract
Cancers must evade or suppress the immune system in order to develop. Better understanding of the molecular regulation governing tumour detection and effective activation of the immune system (so-called immune regulatory checkpoints) has provided new targets for cancer immunotherapy. Therapeutic monoclonal antibodies against these targets are currently undergoing clinical evaluation with more in pre-clinical development; buoyed by the recent licence approval of the anti-CTLA-4 antibody, ipilumumab, for use in melanoma. This article will review the current status of the various antibodies and target molecules being investigated.
This record has no associated files available for download.
More information
Published date: 23 May 2013
Keywords:
immunomodulatory antibodies, monoclonal antibodies, cancer, immunotherapy
Organisations:
Cancer Sciences
Identifiers
Local EPrints ID: 353477
URI: http://eprints.soton.ac.uk/id/eprint/353477
ISSN: 0306-5251
PURE UUID: 4bef3473-f879-4b5f-8556-3968dd8ab410
Catalogue record
Date deposited: 10 Jun 2013 10:24
Last modified: 15 Mar 2024 02:58
Export record
Altmetrics
Contributors
Author:
Chern Siang Lee
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
